EFTReFFECTOR Therapeutics Inc. Common Stock
0.0008USD0.00%Mkt Cap: 3763 $P/E: —4d ago
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap3.76K $
Enterprise Value-5.13M $
Revenue (TTM)—
Gross Profit-21.62M $
Net Income (TTM)-35.81M $
Revenue/Share—
Last Price0.0008 USD
Fiscal Year EndDec 2023
MR QuarterMar 2024
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.16
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)-20.11
EPS (Forward)-2.25
52W Range
0.00026% of range0.0100
52W High0.0100 USD
52W Low0.0002 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE617.96%
ROA-174.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.55M $
CapEx (TTM)97.00K $
FCF Margin—
FCF Yield-469462.56%
Net Debt-5.13M $
Net Debt/EBITDA0.16
Balance Sheet
Debt/Equity-3.55
Current Ratio1.03
Quick Ratio0.99
Book Value/Sh0.2120 USD
Cash/Share5.396 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJan 12, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.70M
Float4.67M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio1.0d
Short % Float1.97%
Short % Out.1.95%
Shares Short91.62K
Short (prev mo.)110.66K
Technical
SMA 500.0004 (+96.1%)
SMA 2000.0003 (+156.8%)
Beta2.41
S&P 52W Chg18.16%
Avg Vol (30d)595
Avg Vol (10d)53
Technical Indicators
RSI (14)68.7
MACD0.0000
MACD Signal-0.0000
MACD Hist.+0.0001
BB Upper0.0009 USD
BB Middle0.0004 USD
BB Lower-0.0002 USD
BB Width296.94%
ATR (14)0.0001 USD
Vol Ratio (20d)0.00x